(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.
Orchestra Biomed Holdings's earnings in 2025 is -$69,699,000.On average, 5 Wall Street analysts forecast OBIO's earnings for 2025 to be -$99,816,907, with the lowest OBIO earnings forecast at -$111,147,475, and the highest OBIO earnings forecast at -$90,104,992. On average, 5 Wall Street analysts forecast OBIO's earnings for 2026 to be -$86,220,226, with the lowest OBIO earnings forecast at -$94,960,950, and the highest OBIO earnings forecast at -$73,918,466.
In 2027, OBIO is forecast to generate -$72,839,365 in earnings, with the lowest earnings forecast at -$75,537,119 and the highest earnings forecast at -$70,141,611.